Kymera rais­es $65M from glob­al syn­di­cate as it aims for the clin­ic with pro­tein degra­da­tion tech

You can add Kymera Ther­a­peu­tics to the list of biotechs at­tract­ing at­ten­tion from an in­ter­na­tion­al set of in­vestors.

The biotech is tak­ing the lid off a $65 mil­lion round that’s been put to­geth­er to help steer the dis­cov­ery-stage com­pa­ny to­ward the clin­ic — a land­mark af­fair for Kymera that isn’t go­ing to ar­rive ahead of 2020.

In­cu­bat­ed by At­las and blessed with a $30 mil­lion launch round a year ago — af­ter start­ing up with seed fund­ing in Lab­Cen­tral in Cam­bridge, MA — Kymera now has the cash to grow the team and the pipeline of pre­clin­i­cal pro­grams. Like oth­ers in the field, their sci­en­tists are fo­cused on hi­jack­ing the body’s ubiq­ui­tin-pro­tea­some sys­tem to dis­pose of pro­teins, bind­ing to pro­teins and mark­ing them for de­struc­tion.

Nel­lo Main­olfi

But they’re do­ing it with a plat­form built on a com­plex ap­proach us­ing in­for­mat­ics-dri­ven tar­get iden­ti­fi­ca­tion cou­pled to pre­dic­tive mod­el­ing, new degra­da­tion tools as well as nov­el E3 lig­as­es and lig­ands. 

“It’s a pret­ty hot field,” Nel­lo Main­olfi, the chief tech of­fi­cer and co-founder, tells me. And the mon­ey gives them a chance to shine more of a light on the tech they’re us­ing at a time that the “po­ten­tial of degra­da­tion is just scratch­ing the sur­face now.”

Lau­rent Au­doly

The cash al­so gives the com­pa­ny, which isn’t say­ing much now about its lead pro­grams, a chance to keep on adding tal­ent, says CEO Lau­rent Au­doly.

Pro­tein degra­da­tion R&D isn’t new. Jay Brad­ner launched C4 Ther­a­peu­tics to blaze the pro­tein degra­da­tion ap­proach just be­fore he took the helm at the No­var­tis In­sti­tute of Bio­med­ical Re­search, then re­cent­ly formed a dis­cov­ery al­liance with UC Berke­ley with the same ba­sic ap­proach in mind. Arv­inas al­so has cen­tered on pro­tein degra­da­tion, build­ing on the lab work of Yale’s Craig Crews.

6 Di­men­sions Cap­i­tal out of Chi­na joined Besse­mer Ven­ture Part­ners and Pfiz­er Ven­tures in co-lead­ing the deal, with par­tic­i­pa­tion by MRL Ven­tures Fund, Sanofi Ven­tures, Hat­teras Ven­ture Part­ners, and Aju IB In­vest­ment, in ad­di­tion to Kymera’s Se­ries A in­vestors. Wei Li of 6 Di­men­sions Cap­i­tal, An­drew Hedin of Besse­mer Ven­ture Part­ners, and Elaine Jones of Pfiz­er Ven­tures will join Kymera Ther­a­peu­tics’ board.

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Phar­ma com­pa­ny con­tin­ues its FDA law­suit spree, this time af­ter agency de­nies fast-track des­ig­na­tion

Vanda Pharmaceuticals is making a name for itself, at least in terms of suing the FDA.

The DC-headquartered firm on Monday filed its latest suit against the agency, with the company raising concerns over the FDA’s failure to grant a fast track designation for Vanda’s potential chronic digestive disorder drug tradipitant, which is a neurokinin 1 receptor antagonist.

Specifically, Vanda said FDA’s “essential point” in its one-page denial letter on the designation pointed to “the lack of necessary safety data,” which was “inconsistent with the criteria for … Fast Track designation.”

Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi therapeutics juggernaut Alnylam Pharmaceuticals made a splash in March when it sued and sought money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which Alnylam claims have been integral to the way both companies’ mRNA-based Covid-19 vaccines work.

But now, Moderna lawyers are firing back, telling the same Delaware district court that Alnylam’s claims can only proceed against the US government in the Court of Federal Claims because of the way the company’s contract is set up with the US government. The US has spent almost $10 billion on Moderna’s Covid-19 vaccine so far.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

(Credit: Shutterstock)

Cracks in the fa­cade: Is phar­ma's pan­dem­ic ‘feel good fac­tor’ wan­ing?

The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.

On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Michael Corbo, Pfizer CDO of inflammation & immunology

UP­DAT­ED: Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.

Pivotal data from the ELEVATE program in ulcerative colitis — which consists of two Phase III trials, one lasting 52 weeks and the other just 12 weeks — illustrate an “encouraging balance of efficacy and safety,” according to Michael Corbo, chief development officer of inflammation & immunology at Pfizer. The company is presenting the results as a late breaker at Digestive Disease Week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf (Michael Brochstein/Sipa USA via AP Images)

House Re­pub­li­cans at­tack Chi­na-on­ly da­ta in FDA sub­mis­sions, seek new in­ves­ti­ga­tion in­to re­search in­spec­tions

Three Republican representatives are calling on the FDA to take a closer look at the applications including only clinical data from China.

The letter to FDA commissioner Rob Califf late last week comes as the agency recently rejected Eli Lilly’s anti-PD-1 antibody, which attempted to bring China-only data but ran into a bruising adcomm that may crush the hopes of any other companies looking to bring cheaper follow-ons based only on Chinese data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right pro­teins; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

It’s always a bittersweet moment saying goodbye, but as Josh Sullivan goes off to new adventures we are grateful for the way he’s built up the Endpoints Manufacturing section — which the rest of the team will now carry forward. If you’re not already, this may be a good time to sign up for your weekly dose of drug manufacturing news. Thank you for reading and wish you a restful weekend.

Bris­tol My­ers Squibb sues No­var­tis for roy­al­ties sur­round­ing the use of trans­genic mice

Two Big Pharma companies are going to the mat over genetically modified mice in a licensing dispute.

Bristol Myers Squibb is suing Novartis in New York over a dispute concerning an evaluation, research and commercialization agreement stretching back to the late ’90s initially inked between Novartis and BMS’ predecessor Medarex. The deal in question allowed Novartis to use Medarex’s patented transgenic mice to develop therapeutic drugs. Novartis agreed to pay Medarex – and subsequently BMS – a royalty on sales of drugs it developed using the mice.

Co­pay coupons gone wrong, again: Pfiz­er pays al­most $300K to set­tle com­plaints in four states

Pfizer has agreed to pay $290,000 to settle allegations of questionable copay coupon practices in Arizona, Colorado, Kansas, and Vermont from 2014 to 2018.

While the company has not admitted any wrongdoing as part of the settlement, Pfizer has agreed to issue restitution checks to about 5,000 consumers.

A Pfizer spokesperson said the company has “enhanced its co-pay coupons to alleviate the concerns raised by states and agreed to a $30,000 payment to each.”